Mar 28, 2024•Press Release
– LRK-A drives monotherapy anti-tumor activity, including complete tumor regressions, in CRC patient samples and an in ...
Jan 10, 2024•PRESENTATION PLAYBACK
Fierce JPM Week panel (3:40pm PST) with CEO Catherine Sabatos-Peyton and other industry experts from Merck, Abbvie and more (...
Dec 14, 2023•Press Release
Watertown, MA — December 14, 2023 – Larkspur Biosciences, a company pioneering a new wave in cancer therapy that stops im...
Oct 25, 2023•Press Release
Research emphasizes the significant role of Pin1 in influencing critical cancer mechanisms to drive a pro-immune response, re...
Jun 26, 2023•Press Release
Research foundational to Larkspur’s newly disclosed TIM-1 program published by founder Vijay K. Kuchroo in Nature Watertown...